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We solved the crystal structure of Burkholderia
pseudomallei acute phase antigen BPSL2765 in
the context of a structural vaccinology study, in the
area of melioidosis vaccine development. Based
on the structure, we applied a recently developed
method for epitope design that combines compu-
tational epitope predictions with in vitro mapping
experiments and successfully identified a consensus
sequencewithin theantigen that,whenengineeredas
a synthetic peptide, was selectively immunorecog-
nized to the same extent as the recombinant protein
in sera from melioidosis-affected subjects. Anti-
bodies raised against the consensus peptide were
successfully tested in opsonization bacterial killing
experiments and antibody-dependent agglutination
tests of B. pseudomallei. Our strategy represents a
step in the development of immunodiagnostics, in
the production of specific antibodies and in the opti-
mization of antigens for vaccine development, start-
ing from structural and physicochemical principles.
INTRODUCTION
Burkholderia pseudomallei is a soil-borne Gram-negative bacte-
rium that causes melioidosis, a debilitating and frequently fatal
disease endemic in the subtropical and tropical regions of the
world (Cheng and Currie, 2005). Melioidosis-affected individuals
display a range of infections, including pneumonia, acute septi-
cemia, localized abscesses, and chronic disease. Such diversity
of symptoms, many of which are common to other pathologies,Chemistry & Biology 20, 1147–115can make it difficult to diagnose the disease. The present treat-
ment for melioidosis relies primarily on antibiotic administration,
but B. pseudomallei exhibits resistance to the main antibiotic
classes (Cheng and Currie, 2005). The combined problems of
timely diagnosis and treatment of the disease contribute to a
high fatality rate. A vaccine against melioidosis would be an
effective option for preventing infection and in controlling relapse
and reinfection, which often occur following antibiotic treatment
(Peacock et al., 2012). However, several vaccination initiatives
have been launched without success (Sarkar-Tyson and Titball,
2010).
Potential protein antigens are likely to be located or excreted
at the cell surface, where they represent the first port of contact
for the molecules that govern the host immune response. In this
context, a recent study employed a protein microarray to display
over a thousand B. pseudomallei proteins, identified via a
reverse vaccinology approach, which was probed with sera
from melioidosis patients to identify immunoreactive proteins
and hence potential antigens (Felgner et al., 2009). As expected,
half of the candidates were designated as outer-membrane or
surface-located proteins and included putative outer-membrane
protein A (OmpA) family members, which have known roles in
bacterial virulence and immunity in other pathogens (Li et al.,
2009; Weiser and Gotschlich, 1991). With regards to OmpAs
fromB. pseudomallei, 12 OmpA genes were identified for subse-
quent immunogenic characterization as potential vaccine candi-
dates, two of which (BPSL2522 and BPSL2765), produced as
soluble recombinant proteins, were confirmed to be immuno-
genic in both mice and melioidosis patients (Hara et al., 2009).
Antibodies against BPSL2765 were found at 10-fold-higher
levels in patients who had only one episode of melioidosis, in
comparison with patients who had suffered recurrent episodes.
However, in mice challenged with ten times the lethal dose of
B. pseudomallei, immunization with recombinant BPSL2765
offered only limited protection (50%), with disease progression6, September 19, 2013 ª2013 Elsevier Ltd All rights reserved 1147
Figure 1. Crystal Structure of PalBp
Ribbon representation of PalBp illustrating three chains (labeled) present in the
asymmetric unit and three acetate ions (spheres), bound at equivalent sites in
each chain. Where visible, the N and C termini of the chains are labeled. This
figure was produced using MacPymol (http://www.pymol.org). See also
Figure S1 and Table S1.
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PalBp Antigen as a Structural Vaccinology Targetcontinuing from the acute to chronic stages of infection (Hara
et al., 2009; Suwannasaen et al., 2011). Thus, to be effective, a
potential vaccine may need to offer protection toward both
phases of infection.
Structure-based antigen engineering could be used to specif-
ically modify protein antigens of a pathogen to enhance their
immunogenic properties, with the aim of improving their protec-
tive efficacy. Moreover, structural information could be used to
design immunodiagnostic probes specific for melioidosis, over-
coming current limitations in diagnosis. Such approaches may
entail engineering only the portions of the protein that house
the epitopes or simply the epitope sequences themselves in
the form of synthetic peptides.
Focusing on the acute phase antigen BPSL2765 as a potential
structural vaccinology candidate, we present a coordinated
study that aims to connect the understanding of structural prop-
erties at the atomic level to the reactivity properties of the protein
(or specific epitopes) in an immunological context.
Specifically, we first solved the X-ray crystal structure of the
protein and used it as the basis for the application of a recently
developed method for epitope design, which combines the
results of computational epitope prediction with those of
in vitro mapping experiments (Lassaux et al., 2013; Peri et al.,
2013). On these bases, a consensus epitope was identified
and a related synthetic peptide was synthesized. When the
peptide was tested for immunoreactivity against sera from
recovered melioidosis patients, it was recognized at levels
comparable with those of the recombinant protein, thus vali-
dating our approach. The immunological properties of the
epitope were further studied in opsonization killing (OPK) tests
using human neutrophils and in assays of antibody-mediated1148 Chemistry & Biology 20, 1147–1156, September 19, 2013 ª201B. pseudomallei agglutination. OPK results indicated that anti-
bodies generated against the epitope were in fact bactericidal,
functioning to enhance neutrophil function, eliminating the
bacteria possibly via an oxidative burst pathway, whereas
agglutination assays confirmed that the antibodies induced
B. pseudomallei-specific agglutination. Notably, both the OPK
and bacterial agglutination tests showed that antibodies raised
against the synthetic epitope were significantly more active
than those generated against the recombinant protein, adding
a second validation stage to our structural vaccinology pipeline
and underlining the potential use of this epitope in melioidosis
vaccine development.
Although we report the specific case of BPSL2765 from
B. pseudomallei, our structural vaccinology strategy is general
and could be applied to produce peptides for the development
of diagnostic tools, for the production of specific antibodies,
and in the general context of antigen optimization for vaccine
development.
RESULTS
Primary Structure Analysis
Based on a protein BLAST search, BPSL2765 exhibits high sim-
ilarity to members of the peptidoglycan-associated lipoprotein
(Pal) family, involved in maintaining outer membrane integrity
and the import of select organic nutrients. At a primary structure
level, Pals typically contain a hydrophobic N-terminal lipoprotein
signal peptide synonymous with bacterial lipoproteins, followed
by a cleavage/modification site and a highly conserved C-termi-
nal OmpA-like domain. Accordingly, a 19-residue signal peptide
containing the LAAC motif, typically found in protein precur-
sors destined for proteolytic processing by signal peptidase II
during translocation across the cytoplasmic membrane, was
predicted using the signal peptide prediction program SignalP
4.1 (http://www.cbs.dtu.dk/services/SignalP/). Furthermore, in
agreement with other Pals, BPSL2765 (hereafter referred to as
PalBp) possesses a highly conserved C-terminal OmpA-like
domain (residues 65–168) that typically houses a peptidoglycan
binding site. Multiple sequence alignment of the genomes of 28
diverse B. pseudomallei strains indicated that BPSL2765 is
100% conserved (data not shown).
PalBp 3D Structure
The crystal structure of PalBp was solved and refined at 2.3 A˚ res-
olution (Table S1 available online). There are three identical PalBp
chains (A, B, and C; root-mean-square deviation [rmsd] values
0.30–0.36 A˚) present in the crystal asymmetric unit (Figure 1).
This trimer is a likely artifact of crystal packing given the absence
of significant trimer interface interactions and the fact that Pal
homologs, including E. coli Pal (Protein Data Bank [PDB] entry
1OAP) and Haemophilus influenzae Pal (PDB entry 2AIZ), with
whom PalBp shares 52% sequence identity, are monomeric
(Parsons et al., 2006). All structural comparisons were made
using PalBp Chain A. As judged by superimposition of PalBp
with E. coli Pal (rmsd of 0.53A˚), using the C-alpha match pair-
wise structural alignment program (http://bioinfo3d.cs.tau.ac.il/
c_alpha_match/), the overall structure conforms to the canonical
a-b sandwich Pal fold, organized in a helix-strand-helix topology
(Figure 1).3 Elsevier Ltd All rights reserved
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each chain, coordinated by identical residues in a small cavity
(vol 108 A˚3) containing main- and side-chain atoms from resi-
dues F70, D71, T104, D105, R107, Y112, N113, L116, R120,
and R162 (Figure 1). All three acetate ions show two alternate
binding modes. The presence of bound acetate and sulfate
ions was also observed in the crystal structures of E. coli Pal in
complex with TolB (PDB entry 2HQS) and alone, respectively.
Computational Epitope Predictions
In order to predict the location of B cell epitopes from the exper-
imental three-dimensional (3D) structure of PalBp, two different
computational methods, matrix of local coupling energies
(MLCE) and electrostatic desolvation profiles (EDP), were com-
bined and applied to representative structures obtained from
molecular dynamics (MD) simulations performed on chain B of
PalBp (Fiorucci and Zacharias, 2010; Scarabelli et al., 2010).
The MLCE approach was developed to identify antigenic
epitopes, whereas EDP is programmed to identify, in addition
to antigen-antibody interaction interfaces, more general pro-
tein-protein interaction interfaces (see Experimental Procedures
and Supplemental Experimental Procedures). Starting from the
idea that structure, dynamics and stability of a protein-antigen
play a key role in the interaction with antibodies, MLCE inte-
grates the analysis of the dynamical and energetic properties
of proteins to identify nonoptimized, low-intensity energetic
interaction-networks on the surface of the isolated antigens,
which correspond to substructures that can aptly be recognized
by a binding partner (the antibody). EDP calculates the free en-
ergy penalty for desolvation by placing a neutral probe at various
protein surface locations. Surface regions with a small free-
energy penalty for water removal may correspond to preferred
interaction sites. Evidence suggests that it is easier for a partner
to bind to an epitope when properties required for efficient bind-
ing, such as low desolvation penalty, are met.
The results individually produced by MLCE and EDP are
reported in Table S2. The sequences of EDP predicted epitope
regions broadly overlap with one another, and all MLCE pre-
dicted residues were also found by EDP. Therefore, MLCE/
EDP consensus regions are those composed of amino acids
identified by both methods; moreover, as MLCE identified fewer
residues than EDP, the resulting consensus regions simply
correspond to the two MLCE-predicted patches (Table S2;
Figure 3).
Experimental Epitope Mapping
In order to complement the computational predictions, epitope
mapping experiments were carried out using recombinant PalBp
and rabbit polyclonal antibodies (see Supplemental Experi-
mental Procedures). To this aim, we adopted and extended an
immunocapturing approach that is successfully usedwithmono-
clonal antibodies (Koehler et al., 2011; Soriani et al., 2010). The
approach involves proteolytic digestion (using different prote-
ases) of the target antigen prior to immunocapturing and sub-
sequent analysis of antibody-bound peptides (containing the
epitope) by mass spectrometry. Using this approach, one
expects polyclonal antibodies to recognize the same epitope
regions, regardless of the protease used to produce the peptide
mixture.Chemistry & Biology 20, 1147–115Partial trypsin digestion of PalBp gave rise to two mass spec-
trometry peaks with m/z values of 3,284.673 Da (peak 1) and
3,440.791 Da (peak 2). To unequivocally assign the sequence
of these peptides, tandem mass spectrometry (MS/MS) spectra
were recorded. Both peaks corresponded to the same antigen
region: peak 1 corresponds to residues 65 to 91, and Peak 2 cor-
responds to the same sequence but with an additional N-termi-
nal residue (Table S2). For the LysC-obtained peptide mixture
(Peak 3), a single peptide (m/z 3,440.818 Da) covering the
sequence from R64 to K91 was immunocaptured and confirmed
by MS/MS (Table S2). GluC digestion in ammonium bicarbonate
shows a preference for cleavage at Glu residues; thus, the pep-
tides immunocaptured from a partial GluC digestion in ammo-
nium bicarbonate buffer should contain the same sequence of
those captured from the trypsin and LysC digestions, but they
should have a Glu residue at the C-terminal end. In fact, for
GluC two different peptides were immunocaptured with m/z
values of 4,137.148 (peak 4) and 4,667.003 (peak 5) Da, respec-
tively. These peptides comprise residues 72 to 106 and 72 to 111
for peaks 4 and 5, respectively (Table S2). The sequence of these
peptides could not be confirmed by MS/MS, so they were
confirmed by peptide mass fingerprinting. Taken together, the
experimental epitope mapping data show that all the immuno-
captured peptides share a common sequence containing
epitope residues that are key for the antibody-antigen interac-
tion; such sequence covers PalBp residues 72 to 91 that, from
a structural point of view, pertain to a loop region followed by a
helix 3 (Figure 2A).
Epitope Design
The results of computational predictions and immunocapturing
experiments were compared to search for common determi-
nants for antibody recognition. Despite the very different condi-
tions and approaches, the protein substructures individually
identified by either MLCE or EDP overlap significantly with those
derived by single protease degradation; for example, MLCE 2
overlaps with the GluC-derived peptides (peaks 4 and 5), while
EDP predictions cover all protease-generated peptides (peaks
1–5; see Table S2).
Overall, the consensus of computational predictions, repre-
sented byMLCE 2, is also present in the experimental consensus
epitope region. Based on this observation and on previous expe-
riencegainedwith theOppAantigen (Lassauxetal., 2013),wepro-
pose that the consensus region hosts key residues for antibody
recognition and binding. It must be underlined, at this point, that
the proposed overall consensus between the computationally
predicted and the immunocaptured sequences is limited to resi-
dues 89–91 (YLK). Three residues are unlikely to elicit antibodies
if used as an immunogenic peptide; however, the consensus
sequence should be considered as starting information for the
design/selection of longer synthetic peptide immunogens.
Inspection of the PalBp 3D structure shows that the consensus
YLK sequence is located in a helix 3, which is built by several res-
idues (residues 76–93) that were also identified by experimental
mapping (Figure 2A; Table S2). From a dynamical point of view,
a helix 3 shows low flexibility (in the intact protein antigen), as
evidenced from analysis of residue-based root-mean-square
fluctuations (rmsf), obtained after projecting the MD trajectory
along the eigenvectors, indicating the principal (nonrandom)6, September 19, 2013 ª2013 Elsevier Ltd All rights reserved 1149
Figure 2. Mapping PalBp Epitopes
(A) Structural representation of the experimentally mapped PalBp epitope. The 3D structure cartoon representation of the PalBp epitope corresponding to residues
72–91 (epitope 3, blue color) is shown with regards to the overall 3D structure. It partially includes a region that houses the peptidoglycan binding site, where the
acetate ion is bound (spheres). The N and C termini of the protein are labeled, as are epitope residues S72 and K91. This figure was generated using MacPymol
(http://www.pymol.org).
(B) Molecular dynamics characterization of PalBp. Residue-based rmsf calculated projecting the trajectory over the three principal eigenvectors from essential
dynamics analysis. Residues belonging to the each epitope are shown in yellow (epitope 1), green (epitope 2), and cyan (epitope 3). This figure was produced
using Grace 5.1.
See also Figure S2.
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includes a loop region, comprising residues 72–76, that are also
present in the experimentally mapped peptide. This helix-loop
motif in the full-length protein resists cleavage by three different
proteases, indicating that it could behave as a unit that is recog-
nized by polyclonal antibodies through a conformational selec-
tion mechanism. In this context, the conformational behavior of
the isolated peptide, corresponding to residues 72–91,was char-
acterized by MD simulations and circular dichroism (CD) spec-
troscopy. Long-timescale simulations in explicit solvent show
that the peptide can populate ordered secondary structures,
transiently populating helical conformations (data not shown).
CDanalysis in the presence of the secondary structure stabilizing
solvent trifluoroethanol (TFE) experimentally confirmed that the
peptide can populate helical conformations (Figure S2; Supple-
mental Experimental Procedures). On this basis, it is possible to
hypothesize that sequence72–91can transiently populate helical
structures in isolation that may be conformationally selected and
recognized by an antibody elicited against it.
Based on these considerations, we decided to synthetize
three different peptides: two peptide sequences corresponded
to MLCE-EDP computational predictions only and were labeled
epitope 1 and epitope 2, and the third sequence was selected to
match the 72–91 experimental peptide (epitope 3).
Epitope Synthesis
The peptides were synthesized using polyethylene glycol (PEG)
units as spacers and coupled to human serum albumin (HSA)
as carrier protein (see Experimental Procedures). When neces-1150 Chemistry & Biology 20, 1147–1156, September 19, 2013 ª201sary, to synthesize peptides of appropriate size, epitopes were
extended by incorporating flanking residues predicted by EDP.
The resulting peptides were designated as follows: epitope 1
(residues 144–169), a linear epitope derived from the consensus
patch MLCE 1 and EDP patches 4 to 6; epitope 2 (residues
132–141 and residues 89–99), a conformational epitope that
houses the consensus tripeptide (residues 89–91) derived from
both in silico and experimental data, extended around residues
from MLCE patch 2 and EDP patches 1 and 2; and epitope 3
(residues 72–91), containing the same consensus tripeptide
(residues 89–91), extended to include additional residues from
a helix 3, identified by experimental mapping. The sequences,
and locations of the final peptides with regards to the global
PalBp structure, are displayed in Table S2 and Figures 3A–3C,
respectively.
Peptide Immunoreactivity to Human Plasma Antibodies
Epitope peptides were tested for their antigenic properties in
antibody recognition experiments in plasma samples collected
from 19 healthy donors and 20 recovered melioidosis cases
(Khon Kaen University and Srinakarin Hospital, Thailand) by
indirect ELISA. Healthy donors were divided into two groups,
seronegative and seropositive subjects, based on indirect
hemagglutinin assay (IHA) antibody titers (see Experimental Pro-
cedures). As previously reported, control experiments showed
that plasma antibodies to PalBp from the recovered group were
significantly higher than those from the seronegative and sero-
positive groups (Mann-Whitney test; p < 0.001 and p < 0.05,
respectively) (Figure 4) (Suwannasaen et al., 2011).3 Elsevier Ltd All rights reserved
Figure 3. PalBp In Silico and In Vitro Epitopes
(A and B) Ribbon secondary representation of the PalBp structure showing the following epitopes. (A) MLCE (red) and EDP (blue) predictions, (B) the synthetic
peptides epitope 1 (yellow) based on the computational consensus alone, and epitope 2 (green), including the three in silico and experimentally mapped
consensus amino acids.
(C) The synthetic peptide epitope 3 corresponding to the experimentally mapped consensus epitope (cyan + violet); the violet stretch highlights the consensus
between in silico and in vitro mapped residues.
See also Table S2.
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that they are not antigenic. Such finding was not unexpected,
given that the former peptide did not contain any residue identi-
fied in the in vitro mapping, and the latter contained only three
residues (residues 89–91) that overlapped with the experimental
epitope. On the other hand, the epitope 3 consensus peptide
was successfully recognized, to the same extent as the recom-
binant protein, confirming that it represents a highly immunore-
active region capable of maintaining its structure and antibody
recognition properties even in the form of an isolated sequence
fragment. As previously mentioned, CD experiments on the iso-
lated peptide support this view; no features of random coil
‘‘structure’’ were detected (Figure S2). Rabbit polyclonal anti-
epitope 3 antibodies were raised for further validation through
OPK and bacterial agglutination experiments (see Supplemental
Experimental Procedures).
Neutrophil Opsonization Killing Experiments
We first investigated the effect of various concentrations of anti-
epitope 3 antibodies on phagocytosis and oxidative burst
functions of purified human neutrophils, in response to live
B. pseudomallei. As shown in Figure 5A, approximately 95% of
the harvested neutrophils produced superoxide when induced
by phorbol 12-myristate 13-acetate (PMA; positive control) for
15min. In a parallel group, approximately 50%of purified neutro-
phils could phagocytose B. pseudomallei within 60 min. The
phagocytosis and oxidative burst by neutrophils (n = 3) exposed
to B. pseudomallei was significantly enhanced (p < 0.05) by the
presence of anti-epitope 3 antibodies at 10 mg/ml (Figure 5B).
Complement was not added in all of these experiments, indi-
cating that antibodies to epitope 3 alone are sufficient for
enhancing phagocytosis and oxidative burst functions in humanChemistry & Biology 20, 1147–115neutrophils in vitro. Notably, OPK tests carried out with anti-
bodies raised against full-length recombinant PalBp did not
enhance bacterial killing (results not shown).
Next, we investigated the effect of different antibody concen-
trations used to opsonize the bacteria on the ability of human
neutrophils to kill B. pseudomallei. An increase of bacterial killing
activity of purified neutrophils was observed in B. pseudomallei
cells treated with high concentrations of anti-epitope 3 anti-
bodies, compared to those in the absence of opsonin, confirm-
ing an enhancement of antibody-dependent bactericidal activity
in the assay (Figure 5C).
Detection and Agglutination of B. pseudomallei by
Antibodies Generated toward PalBp and Epitope 3
Agglutination by antibody is an additional important defense
mechanism that aids clearanceof pathogens (Bull, 1915; Pal’tsyn
et al., 1999). We determined antibody-mediated agglutination of
B. pseudomallei using anti-PalBp or anti-epitope 3-antibodies
and found that both were able to agglutinate B. pseudomallei,
but not E. coli, indicating that the antibody-mediated agglutina-
tion is bacteria specific (Figure 6). Interestingly, anti-epitope 3
antibodies agglutinated B. pseudomallei more efficiently than
antibodies toward the whole protein, with the majority of the
bacteria having formed aggregates after 30min (Figure 6). Agglu-
tination did not occur when B. pseudomallei was exposed to
PBS, preimmune sera from the same rabbit (prebleed), or anti-
body toward the B. pseudomallei capsule (4V1H12).
DISCUSSION
In the vaccine design/development field, structural vaccinology
has emerged as an innovative tool to help tailor protein antigens6, September 19, 2013 ª2013 Elsevier Ltd All rights reserved 1151
Figure 4. Antibody Response to PalBp Peptides in Plasma of Healthy and Recovered Melioidosis Subjects
Recombinant PalBp protein (A) and synthetic peptides, epitope 1 (B), epitope 2 (C), and epitope 3 (D), were coated onto ELISA plates and probed with diluted
plasma samples of healthy controls, seropositive individuals (n = 12) tested by means IHA (titer > 40), seronegative individuals (n = 7), and recovered melioidosis
patients (n = 20) and quantified by indirect ELISA. Data represent the absorbance index (AI) of individual samples = (O.D. of tested  O.D. of uncoated)/ O.D. of
uncoated. Experiments were performed in duplicate and results represent the mean (AI) ± SE; *p < 0.05; **p < 0.01. ns, nonsignificant.
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effective, and, when necessary, cross-protective vaccines (Dor-
mitzer et al., 2008). Antigens may be engineered to be biochem-
ically more stable by isolating and producing only the minimal
antigenic portions of the protein, which in some cases may be
represented by domains or peptides. Furthermore, structure-
based antigen engineering may be adopted to devise cross-pro-
tective vaccines that address pathogen antigenic variation or to
developmultistage vaccines that take into account diverse path-
ological phases of a disease that may display different antigens
(Aagaard et al., 2011; Nuccitelli et al., 2011).
Previous work has shown that antibodies against
B. pseudomallei can play a key role in protection against melioi-
dosis. In humans, the antibody titer to bacteria is broadly
correlated with disease severity (Wiersinga et al., 2006). In
small-animal models of infection (diabetic rats or mice), the pas-
sive transfer of antibodies against surface polysaccharides
provides protection against a subsequent challenge; these anti-
bodies appear to be opsonizing (Nelson et al., 2004; Zhang et al.,
2011). Conversely, the role of antibodies to proteins in protective
immunity is generally less clear. Antibody to flagellin has been
shown to inhibit the motility of B. pseudomallei, and antibodies
against PalBp are reported to promote complement-mediated
killing and phagocytosis by neutrophils (Brett and Woods,
1996; Su et al., 2010).
Our work presents and validates a 3D structure-based
approach, combined with in vitro and immunological tests, to
determine the location of B cell epitopes within PalBp, an
acute antigen and peptidoglycan-associated lipoprotein from
B. pseudomallei. Based on our results, three epitope peptides
were identified, synthesized, and tested for their antigenicity
against immune sera from melioidosis patients. The PalBp 2.3 A˚
resolution crystal structure, which displayed the canonical a-b
sandwich fold of the Pal family, was used as a template for the
application of MLCE and EDP epitope prediction methods.
Cross-validating the computational predictions with proteoly-
sis-based epitope mapping experiments, combined to the anal-1152 Chemistry & Biology 20, 1147–1156, September 19, 2013 ª201ysis of the protein’s conformational dynamics, led us to identify
one sequence stretch (epitope 3) that hosts key residues neces-
sary for antibody recognition. In ELISA tests, the synthetic pep-
tide corresponding to epitope 3 allowed to distinguish between
healthy and melioidosis-affected individuals, displaying a reac-
tivity profile comparable to that of the recombinant protein
control.
In order to explore the potential of our integrated approach
and the immunological properties of epitope 3 in more detail,
we tested the ability of the peptide to raise opsonizing antibodies
that induce bacteria killing. Since our method has recently
proven that it is possible to use synthetic peptides to raise anti-
bodies that retain full specificity for the epitope region and fully
recognize the full-length protein (Peri et al., 2013), we expected
specific anti-epitope 3 antibodies to enforce bacterial killing,
thus activating the polymorphonuclear cell (PMNC)-mediated
immune response. Indeed, our findings demonstrated a mecha-
nism of antibody-dependent killing of B. pseudomallei with anti-
epitope 3 antibodies acting to significantly boost the bactericidal
activity of human neutrophils via enhanced phagocytosis and
oxidative burst. No complement components were present in
the conditions and the anti-epitope 3 antibodies alone were
seen to enhance bactericidal activity of human neutrophils
through increase phagocytosis and oxidative burst. It has been
shown that the capsular polysaccharide of B. pseudomallei con-
tributes to its resistance to in vitro phagocytosis by reducing C3b
deposition on the bacterial surface (Reckseidler-Zenteno et al.,
2005), which is necessary for killing the bacterium, via NADPH-
oxidase induction by human neutrophils (Woodman et al.,
2012). However, our studies show that antibodies can overcome
bacterial resistance to neutrophil-mediated phagocytosis and
killing, suggesting that treatment strategies to improve anti-
body-mediated opsonization, such as passive or active immuni-
zation, might be beneficial in preventing or altering the course of
infections due to B. pseudomallei.
Bacterial agglutination is a defense mechanism whereby anti-
bodies recognize and bind to surface antigens on multiple3 Elsevier Ltd All rights reserved
Figure 5. Anti-EPITOPE 3 Increased Phagocytosis, Oxidative Burst,
and B. pseudomallei Killing by Human Neutrophils
Purified neutrophils were incubated with medium alone; SYTO 9 fluorescein-
conjugated live B. pseudomallei, or PMA.
(A) Flow cytometry histogram from one representative of three subjects.
Phagocytosis is analyzed measuring the fluorescence intensity (FI) of SYTO 9
in human neutrophils after incubation with labeled bacteria. The positive
control for oxidative burst is evaluated measuring the FI of hydroethidine (HE)
upon incubation with PMA.
(B and C) Overall percentages of phagocytosis and oxidative burst by flow
cytometry (B) and total killing of B. pseudomallei by standard colony counting
(C) from three healthy subjects, assayed in the absence or presence of anti-
epitope 3 are shown. Data represent means ± SE; *p < 0.05.
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gates. Agglutination of bacteria, in this way, enables more
efficient clearance of the bacteria by phagocytes, as well as hin-
dering the bacteria from translocation through tissue barriers
where they could cause more serious infection (Bull, 1915). It
also renders the bacteria, residing in the middle of the cluster,
devoid of oxygen and nutrients, thus facilitating death of the
microbes (Pal’tsyn et al., 1999). In support of our findings that
epitope 3 represents a highly immunogenic region of PalBp
(being recognized to the same extent as the recombinant protein
in sera from recovering human melioidosis patients and eliciting
bactericidal antibodies), we also demonstrated that anti-epitope
3 antibodies specifically agglutinate B. pseudomallei. Interest-
ingly, in both agglutination and OPK tests, antibodies raised
against epitope 3 were active to a greater extent in comparison
with antibodies generated against the recombinant protein. This
could be due to the smaller recognition sequence, or this
epitope could be more efficiently exposed to the host immune
system. Although PalBp strongly reacts toward anti-sera from
B. pseudomallei-infected humans and animals and immunization
of mice prolongs median survival (Hara et al., 2009), incomplete
bacterial clearance was demonstrated via splenomegaly and
abscess formation. Therefore, identification of epitope 3 as a
highly immunogenic portion of PalBp is an important result and,
in contrast to the full-length protein, it may offer enhanced pro-
tection in mice, and ultimately humans, against B. pseudomallei.Chemistry & Biology 20, 1147–115Since PalBp has been shown to offer only partial protection
in mice immunization experiments, it is unlikely to represent a
vaccine candidate alone; it is nevertheless an acute phase
protective antigen and, together with other antigens, including
chronic stage ones, its effects could be potentiated in a multi-
stage vaccine, as exemplified by the recent example of the
M. tuberculosis vaccine (Aagaard et al., 2011; Hara et al.,
2009). Furthermore, our findings stress the concept that it is
possible to (1) employ single immunogenic peptides as vaccine
components, (2) use synthetic peptides to produce specific
antibodies to be employed as adjuvant therapy in acute cases,
and (3) exploit peptide-antibody recognition for diagnostic pur-
poses when strong specificity and sensitivity is established.
Thus, epitope 3 could be used as an alternative to full-length
PalBp, considering that antigenic peptides may be easily conju-
gated to other antigens, bypassing more complex design
schemes, such as the production of chimeric subunit vac-
cines based on whole proteins. Moreover, epitope peptides,
coupled to gold nanoparticles that act as antigen-presenting
platforms, provide an innovative area that is under consider-
ation for vaccine development; such an approach may foster
the design and application of whole libraries of antigenic
peptides, pertaining to diverse antigens, for the production of
multivalent vaccines (Fujita and Taguchi, 2011). For melioido-
sis, generating a library composed of antigenic peptides from
acute and chronic phase antigens may prove the most fruitful
approach.
As a final consideration, our structure-based in silico epitope
prediction pipeline, coupled to validation experiments, could
be applied to screening several antigen structures, determined
directly or via homology modeling, in order to generate large
databases of potential epitopes for subsequent synthesis as
peptides and for immunological testing. Such an approach,
which presently requires further validation on a larger set of
antigens, would represent a significantly improved alternative
to conventional means of epitope identification.
SIGNIFICANCE
Our key finding is the prediction, identification, synthesis,
and immunological validation of a highly immunogenic
epitope based on the combined experimental and computa-
tional analysis of the crystal structure of PalBp, an acute
phase protein antigen from B. pseudomallei, the Gram-
negative bacterium responsible for melioidosis. Using this
approach, we identified a consensus epitope from the anti-
gen structure that, when synthesized as a peptide, was
selectively recognized in sera from melioidosis-affected
subjects and elicited bactericidal antibodies with improved
immunological activities relative to the native antigen.
Such validation experiments on cell cultures show that our
current knowledge on protein structure, dynamics, and
physicochemical properties is mature enough to support
productive experimentation in the structural vaccinology
field. For PalBp, the next step will be to test the epitope in
in vivo immunization tests, either alone or conjugated to
other acute and/or chronic stage antigens. Our structural
vaccinology approach is of general validity and can immedi-
ately be extended to other known antigen structures to6, September 19, 2013 ª2013 Elsevier Ltd All rights reserved 1153
Figure 6. Agglutination of B. pseudomallei after Exposure to Anti-
bodies Raised against PalBp or Epitope 3
RFP-expressing B. pseudomallei or E. coli were incubated with 1 mg of
antibodies for 30 min at 37C. Bacterial agglutination was observed
under epifluorescence microscopy, and the images are representative
of three independent experiments. Red arrows indicate agglutination of
B. pseudomallei after incubation with PalBp. Magnification =3100. All controls
were negative for agglutination with B. pseudomallei, and all samples incu-
bated with E. coli showed the same amount of background agglutination,
which can be attributed to natural agglutination.
Chemistry & Biology
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validation in the discovery of vaccine candidates, but also
for the development of immunodiagnostic tools.1154 Chemistry & Biology 20, 1147–1156, September 19, 2013 ª201EXPERIMENTAL PROCEDURES
Chemicals
All chemicals were obtained from Sigma-Aldrich unless otherwise stated.
PalBp Production, Crystallization, Data Collection, and Structure
Determination
The BPSL2765 gene was amplified from B. pseudomallei strain K96423
genomic DNA, cloned into pET-14b (Novagen), and expressed as a His-tag
fusion protein in BL21 Star (DE3) cells (Invitrogen) (Figure S1). The protein
was purified by affinity chromatography on a 1 ml HisTrap FF column
(GE Healthcare). Following thrombin cleavage of the His-tag, purified PalBp
was crystallized using the sitting drop vapor diffusion method (see Supple-
mental Experimental Procedures for more details). Diffraction data were
collected at a resolution of 2.3 A˚ at the European Synchrotron Radiation Facil-
ity (Grenoble, France) beamline ID14-1. The 3D structure of PalBp was solved
by molecular replacement using the structure of the periplasmic domain of
the Pal protein from E. coli (PDB entry 1OAP; unpublished data) as a search
model (50% sequence identity), as described in Supplemental Experimental
Procedures.
Molecular Dynamics Simulations and Analyses
The simulation and analysis of the PalBp crystal structure were performed
using the GROMACS 4.51 software package (Hess et al., 2008), GROMOS96
force field (van Gunsteren et al., 2006), and the SPC water model (Berendsen
et al., 1987). See Supplemental Experimental Procedures for details.
MLCE Epitope Predictions
Epitope predictions were carried out on the representative structure of the
most populated structural cluster obtained using the method developed by
Daura et al. (1999). The MLCE method (Scarabelli et al., 2010) is based on
the eigenvalue decomposition of the matrix of residue-residue energy cou-
plings, available as the free web tool BEPPE (http://bioinf.uab.es/BEPPE).
For more detailed information, see Supplemental Experimental Procedures.
EDP Epitope Predictions
In order to increase the consistency of the epitope predictions, the MLCE
output was intersected with the EDP output for consensus surfaces. The
EDP method calculates the free energy penalty for desolvation placing a
neutral probe at various protein surface positions. Surface regions with a small
free energy penalty for water removal may correspond to preferred interaction
sites. Evidence suggests that it is easier for an antibody to bind to an epitope
when properties required for high-affinity binding like low desolvation penalty
are met (Westhof et al., 1984).
Experimental Epitope Mapping with Polyclonal Antibodies
Peptide mixtures were obtained by digestion with trypsin and endoprotei-
nases, LysC and GluC, followed by immunocapture of the epitope-containing
peptides on Dynabeads Pan Mouse IgG. Subsequent MALDI-MS analysis of
captured fragments was carried out to identify their sequences. See Supple-
mental Experimental Procedures for a full description of the entire procedure.
Synthesis of Epitope Peptides
Epitope sequences for peptide synthesis were designed based on a compar-
ison of the consensus results of the two computational predictions and exper-
imental epitope mapping. All three peptides (epitopes 1–3) were produced via
solid-phase synthesis.
In view of their use as immunogens to induce antibody production, the orig-
inal peptides were elongated in two cases (epitopes 1 and 2) by including
flanking residues at the N andC termini, based on the consideration that longer
sequences induce better immunogenic responses (Purcell et al., 2007). A
cysteine residue preceded the PEG group to facilitate conjugation to HSA,
the carrier protein. All peptides were prepared in free- and HSA-conjugated
forms. Epitope 2 is a discontinuous conformational epitope composed of
two short peptides that are brought close together in the tertiary structure.
Measurement of the average distance between the termini of patch 1 from
MD simulations suggested that insertion of a PEG (molecular weight, 308.16)
moiety would be sufficient to bridge the two short sequences.3 Elsevier Ltd All rights reserved
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Epitope 3 peptides were specifically conjugated to freshly prepared malei-
mido-activated hemocyanin from Concholepas and rabbit serum albumin
using sulfosuccinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate
(Sulfo-SMCC) according to the procedure described by Liu et al. (1979).
Serum PalBp Antibody Concentration Determination
The concentration of antigen-specific antibodies in the terminal immune sera
was determined by ELISA as described in the Supplemental Experimental
Procedures.
Agglutination Assay
RFP-expressing K96243 (Wand et al., 2011) or E. coli 29522 (American Type
Culture Collection), as negative control, were subcultured from overnight
broths into LB and grown to log phase. Bacteria (1 3 108) were incubated
with either 1 mg PalBp anti-sera or 1 mg antibodies toward epitope 3 recon-
stituted in PBS. Controls were prebleed from the immunized rabbit,
B. pseudomallei capsule antibodies 4V1H12 (Cuccui et al., 2012), and PBS
alone. Incubation was performed static at 37C for 30 min. A 30 ml aliquot of
culture was placed onto a glass coverslip and allowed to air dry before fixing
in 1% paraformaldehyde for 10 min. Coverslips were washed three times in
PBS and mounted onto glass microscope slides using Vector shield hardset
mounting media with DAPI (Vector Laboratories). Epifluorescence microscopy
was used to discern bacterial agglutination (Zeiss).
Human Plasma Sample Preparation
Plasma samples were collected from healthy volunteers (n = 19) at the Blood
Bank Center, Khon Kaen University, and from recovered melioidosis patients
(n = 20) at Srinakarin Hospital, Khon Kaen University and Ubon Ratchathani,
Northeast Thailand, with informed consent. Ethical permission was obtained
from Ethical KKU research no. HE470506. For details, see Supplemental
Experimental Procedures.
Indirect ELISA to Detect Antibodies to B. pseudomallei
Antibody recognition of the three synthesized peptides (epitopes 1–3) was
detected using indirect ELISA using 96-well microtiter plates (Nunc Maxisorp)
that were uncoated or coated with 50 ml/well of 10 mg/ml of recombinant PalBp
as a control or 3 mg/ml peptides epitope 1, epitope 2, and epitope 3 in 0.1 M
carbonate-bicarbonate buffer (pH 9.6), incubating at 37C for 3 hr. Immunore-
activity was revealed, probing the plates with 1:300 diluted plasma samples
from healthy and recovered melioidosis subjects. See Supplemental Experi-
mental Procedures for additional information.
Neutrophil Isolation
Human neutrophils were freshly isolated from heparinized venous blood by
3.0% dextran T-500 sedimentation and Ficoll-PaquePLUS centrifugation
(Amersham Biosciences). In general, neutrophil purity was >95%, as deter-
mined by Giemsa staining and microscopy, while cell viability was >98%, as
determined by trypan blue exclusion (Egan and Gordon, 1996).
Labeling of Bacteria with SYTO9
LiveB. pseudomallei at a concentration of 13 108CFU/ml were incubatedwith
5 mMSYTO9 Green-Fluorescent Nucleic Acid Stains (Syto9) (Invitrogen) in the
dark at room temperature for 30 min, and Syto9 labeled live B. pseudomallei
intensity was analyzed by flow cytometry (FACSCalibur; BD Biosciences)
prior to use. Syto9-labeled bacteria were used only once and discarded
after use.
Phagocytosis and Oxidative Burst Assayed by Flow Cytometry
Purified neutrophils were treated withmedium alone or anti-epitope 3 antibody
at concentrations of 0.1, 1, and 10 mg/ml for 30 min, before incubation with
Syto9-labeled live B. pseudomallei, at a multiplicity of infection (MOI) of 1:1
for 60 min or with 800 ng/ml PMA (Sigma) as a positive control for oxidative
burst for 15 min at 37C; then 25 ml of a 2,800 ng/ml hydroethidine (Sigma)
solution was added and the preparation was incubated for 5 min at 37C. Cells
were washed twice and fixed with 10% paraformaldehyde for decontamina-
tion prior to analysis by flow cytometry (FACSCalibur; BD Biosciences) (Chan-
chamroen et al., 2009).Chemistry & Biology 20, 1147–115Total Bacterial Killing Assay
Purified neutrophils were treated with anti-epitope 3 antibodies as described
above prior to infection with B. pseudomallei at a MOI of 1:1 and incubated
at 37C for 60min. Then, infected cells were lysed by 1%Triton X-100 and total
bacterial killing was determined by standard bacterial plating on Luria-Bertani
agar plates and count the numbers of bacterial colony after 24 hr.
ACCESSION NUMBERS
The Protein Data Bank (http://www.pdbe.org) accession code for atomic
coordinates and structure factors relative to the crystal structure of PalBp,
reported in this paper, is 4B5C.
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